Hospital or health organisation · founded 1876
The University of Texas MD Anderson Cancer Center
Houston, United States · mdanderson.org
- Citations, last 5 years
- 470.2k
- Works, last 5 years
- 44.3k
- h-index
- 1,800
- Scientists listed
- 5 302
- Grants since 2016
- 2 323
Grants received
2021–2026 · research · R01
New Therapeutic Approaches for Stratified High-REST GBM Subtype
Sadhan Majumder · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2026 · research · R00
Functional characterization of novel oncogenic loci driving progression and immune response in gastrointestinal cancer
Yuan-Hung Lo · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Alzheimer's Disease Pathology in a Primate Model
William D Hopkins · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis
Michael Richard Green · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2026 · research · R01
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2
Jonathan M Kurie · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2026 · research · R01
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
Timothy Anthony Yap · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Pro-Drug Enolase Inhibitors in Precision Oncology
Steven W Millward · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Targeting replication stress and homologous recombination repair mechanisms in HPV-positive and negative head and neck cancer
Mitchell J. Frederick · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
RNase H2 is a novel therapeutic target in triple negative breast cancer
Shiaw-Yih Lin · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer
Shiaw-Yih Lin · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
Juan Fueyo · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis
Xiangsheng Zuo · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2026 · cooperative agreement · U01
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
Lauren Averett Byers · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Testing the impact of a multi-level intervention on cancer prevention behavior among young adults in Texas
Qian Lu · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2026 · cooperative agreement · U24
A Genome Data Analysis Center Focused on Batch Effect Analysis and Data Integration
Rehan Akbani · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R25
Helping Everyone Achieve a LifeTime of Health - Future Addiction Scientist Training
Ezemenari M. Obasi · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities
Jlenia Guarnerio · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2027 · research · R01
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer
Humam Kadara · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2026 · research · R01
Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer
Andrea Viale · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2021–2026 · research · R50
Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)
Monique B Nilsson · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2025 · research · R01
Breaking down tumor immune privilege through targeted hypoxia reduction
Michael A. Curran · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2025 · program · P01
Mechanisms controlling distinct growth and functional characteristics of the perinatal and adult thymus
Ellen R Richie · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2025 · research · R35
Computational approaches for protein functional analysis using CRISPR screens
Han Xu · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2024 · grant · Standard Grant
NSF/MCB-BSF: TWIST1 post-translational modification crosstalk in EMT
Mark Bedford · The University of Texas MD Anderson Cancer Center · funded by National Science Foundation
2020 · grant · Academic Research
Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance
Liuqing Yang · The University of Texas MD Anderson Cancer Center · funded by Cancer Prevention and Research Institute of Texas
2020–2022 · research · R21
Prostate cancer-associated SPOP mutations modulate innate immune response and immune checkpoint therapy
Samir M Hanash · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020 · grant · Academic Research
Targeting MEK in EGFR-Amplified Glioblastoma
W. K. Alfred Yung · The University of Texas MD Anderson Cancer Center · funded by Cancer Prevention and Research Institute of Texas
2020–2024 · research · R01
Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients
David Hui · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2025 · research · R01
Molecular Photoacoustic Imaging for Diagnostics and Therapy Monitoring
Richard R. Bouchard · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020 · grant · Academic Research
Development of a Novel Strategy for Tumor Delivery of MHC-I-Compatible Peptides for Cancer Immunotherapy
Zhen Fan · The University of Texas MD Anderson Cancer Center · funded by Cancer Prevention and Research Institute of Texas
2020 · grant · Academic Research
Targeting B Cells to Enhance Responses to Immune Checkpoint Blockade
Jennifer Wargo · The University of Texas MD Anderson Cancer Center · funded by Cancer Prevention and Research Institute of Texas
2020–2023 · research · R01
Molecular mechanisms underlying immunosuppression and inflammation caused by SARS-CoV2 proteins
Shao-Cong Sun · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2025 · research · R01
Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML
Kapil Bhalla · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2025 · research · R50
Identifying the vulnerabilities in Mdm2 overexpressing cancer cells
Vinod Pant · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020 · grant · Academic Research
Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBMl0-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy
Ferdinandos Skoulidis · The University of Texas MD Anderson Cancer Center · funded by Cancer Prevention and Research Institute of Texas
2020–2023 · research · R21
Prostate cancer-associated SPOP mutations modulate innate immune response and immune checkpoint therapy
Samir M Hanash · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2025 · research · R01
Breaking down tumor immune privilege through targeted hypoxia reduction
Michael A. Curran · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2022 · research · R01
Molecular mechanisms regulating TLR signaling and inflammation
Shao-Cong Sun · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2023 · research · R34
Pilot Study to Evaluate a Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers
Janice Anita Blalock · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
2020–2024 · research · R01
The interplay of the immune system, and microbiome in determining outcome of respiratory viral infections in hematopoietic cell transplant recipients and in patients with leukemia
Marjorie Batista · The University of Texas MD Anderson Cancer Center · funded by National Institutes of Health
